Asclepius Biosciences is a POC Dx company whose mission is real time monitoring of biologics to significantly improve patient care.

Biologics have revolutionized the treatment of autoimmune disease & cancer. However, there is growing evidence that after a short period of being on the drug, the patients start to lose response. This has created a need to titrate the drug dose before the next infusion. Today, this is done in CLIA with a turn around time of two weeks.
Our initial market is IBD (Inflammatory bowel disease), based on the founder’s relationship with clinicians. Our POC assay will empower physicians to do the test in their infusion centers and determine the results in real time (20 Minutes).

We will leverage the same POC technology to commercialize drug specific POC test for RA and oncology addressing large markets.

Our management team has a successful track record of developing and commercializing technologies with millions of $ in revenue.